Bristol-Myers Squibb (BMY) Misses Q3 EPS by 2c, Beats on Revenues; Lowers FY17 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
Go back to Bristol-Myers Squibb (BMY) Misses Q3 EPS by 2c, Beats on Revenues; Lowers FY17 EPS Guidance
October 30, 2017 7:00 AM EDT
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Medicines Agency (EMA) validated its type II variation application, which seeks to expand the current indications for Opdivo (nivolumab) to include the treatment of patients with melanoma who are at high risk of disease recurrence following complete surgical resection. Validation of the... More
October 30, 2017 6:47 AM EDT
SunTrust Robinson Humphrey upgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Hold to Buy with a price target of $75.00 (from $55.00).
For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click... More
October 26, 2017 1:04 PM EDT
JPMorgan maintains Overweight on Bristol-Myers Squibb Co. (NYSE: BMY).
Analyst Chris Schott says the overall results for Q3 were solid and that the weakness in the stock today is unwarranted. The analyst reminds client the next catalyst he sees for upside... More
